Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥ 18 years of age, at the time of signing the informed consent form (ICF).~2. Relapsed and/or primary refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) with subtype refractory anemia with excess blasts (RAEB)-2 defined as high or very high-risk that is recurrent or refractory, or the patient is intolerant to established therapy.~3. Subject consents to hospitalization for first (Cycle 1 Day 1) dose of CC-90002 and for 72 hours after.~4. Subject consents to serial bone marrow aspiration and biopsies as specified.~5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.~6. Eligible study subjects must exhibit acceptable liver, renal, and coagulation function as assessed by laboratory tests.~7. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and for up to 8 weeks following the last dose of CC 90002.~Exclusion Criteria:~1. Active central nervous system (CNS) leukemia or known CNS leukemia.~2. Immediately life-threatening, severe complications of leukemia.~3. Impaired cardiac function or clinically significant cardiac diseases.~4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency.~5. Prior autologous hematopoietic stem cell transplant ≤ 3 months.~6. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months.~7. Systemic immunosuppressive therapy post HSCT or with clinically significant graft-versus-host disease (GVHD).~8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks whichever is shorter.~9. Major surgery ≤ 2 weeks and recovered from any clinically significant effects of recent surgery.~10. Pregnant or nursing females.~11. Known HIV infection.~12. Known chronic hepatitis B or C (HBV/HCV) infection.~13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.~14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.~15. History of concurrent second cancers requiring active, ongoing systemic treatment.~16. Subjects for whom potentially curative anticancer therapy is available.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation of CC-90002 (Type: EXPERIMENTAL): CC-90002 by intravenous (IV) infusion on a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).